Are Ozempic and Wegovy still being made?
Yes, with expanded production after the Catalent acquisition.
Did Novo Nordisk stop making Ozempic?
No.
Why are people asking if semaglutide is going away?
Confusion with the February 2025 shortage resolution and its effect on compounded availability.
Is there still a semaglutide shortage?
No. Resolved February 21, 2025.
Will Wegovy be discontinued?
No. Expanding indications including the 2024 cardiovascular approval.
Can I still get semaglutide in 2026?
Yes, through prescription.
Is the patent expiring?
Not until the early 2030s.
What new drugs might replace semaglutide?
Investigational drugs are additions, not replacements.
Is Wegovy self-pay available?
Yes, $499/month through NovoCare.
Related guides
- Is Tirzepatide Going Away? Brand vs Compounded Availability in 2026
- Is Compounded Semaglutide Going Away? The February 2025 Decision Explained
- Is Compounded Tirzepatide Going Away? What Actually Changed in October 2024
- What's the Lowest Cost Semaglutide Option in 2026? Brand-Name vs Compounded Pricing Explained
- What Is the Most Affordable Semaglutide Option in 2026? (Brand vs Compounded vs Assistance Programs)
- How to Access Affordable Tirzepatide in 2026: Brand vs Compounded Cost Breakdown
Sources
- FDA Drug Shortage List update, February 21, 2025, resolving semaglutide shortage
- Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM, March 2021 (STEP 1)
- Lincoff AM et al., "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," NEJM, November 2023 (SELECT)
- Novo Holdings press release, Catalent acquisition completion, December 2024
- Ozempic FDA prescribing information, December 2017 with updates
- Wegovy FDA prescribing information, June 2021 with updates
- Wegovy cardiovascular indication approval, FDA, March 2024
- Rybelsus FDA prescribing information, September 2019
- NovoCare Wegovy Self-Pay program announcement and expansion
- Federal Food, Drug, and Cosmetic Act Sections 503A and 503B
- U.S. Patent and Trademark Office records on semaglutide patents
- Cagrisema, retatrutide, orforglipron Phase 3 trial registrations (clinicaltrials.gov)
- Endocrine Society Clinical Practice Guideline on Obesity, 2023
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform connecting patients with licensed prescribers for evaluation and prescription of GLP-1 therapy. We do not manufacture or dispense medications directly; clinical and pharmacy decisions rest with licensed professionals.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Compounded Medication Notice. Compounded semaglutide is prepared by licensed 503A pharmacy partners for individual patients with documented clinical justification. It is not FDA-approved. Brand Ozempic and Wegovy have specific clinical trial backing (STEP and SELECT programs) that does not transfer to compounded preparations.
Results Disclaimer. Outcomes vary. STEP 1 reported a 14.9% mean weight loss at week 68 for semaglutide 2.4 mg. Your result will depend on adherence, dose, baseline weight, and individual response. Adverse events including gastrointestinal effects, gallbladder events, and pancreatitis are possible.
Trademark Notice. Ozempic, Wegovy, Rybelsus, and NovoCare are trademarks or service marks of Novo Nordisk A/S. FormBlends is independent and not affiliated with Novo Nordisk.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →